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Abstract
We aimed to assess the incidence and risk factors of secondary malignancy (SM) in the young adult patients who received
high-dose chemotherapy (HDCT) for germ cell tumors (GCT). The EBMT database was interrogated. Criteria for patient
selection included adult male GCT and HDCT administered in any line of therapy. Cumulative incidence methods were used
to estimate the time-to-SM diagnosis. Univariable Fine and Gray proportional hazard regression evaluated risk factors of SM
occurrence. From 1981 to 2015, 9153 autografts were identified. Among 5295 patients, 59 cases of SM, developed after a
median follow-up of 3.8 years, were registered. Of these patients, 23 (39%) developed hematologic SM, 34 (57.6%) solid
SM (two patients had uncoded SM). Twenty-year cumulative incidence of solid versus hematologic SM was 4.17% (95%
CI: 1.78–6.57) versus 1.37% (95% CI: 0.47–2.27). Median overall survival after SM was significantly shorter for patients
who developed hematologic SM versus solid SM (8.6 versus 34.4 months, p= 0.003). Age older than 40 years at the time of
HDCT was significantly associated with hematologic, but not solid, SM development (p= 0.004 versus p= 0.234). SM
occurrence post-HDCT showed different patterns of incidence and mortality in GCT. These data may be important to
optimize patient selection, counseling and follow-up after HDCT.
Introduction
Germ cell tumors (GCT) are classified among the rare solid
tumors of the adults, although they are typically diagnosed
in young adult men of 25–35 years of age [1]. Their esti-
mated incidence is of 3.29 patients per 100,000 annually in
Europe [2]. In patients presenting with metastatic GCT,
first-line cisplatin-based chemotherapy, with or without
consolidation surgery or radiotherapy according to the his-
tologic subtype, is associated with an overall survival (OS)
>90% in most cases [1]. For the few patients who progress
after platinum-based chemotherapy, no therapeutic standard
exists. Since the last few decades, there is an ongoing
debate among the GCT experts as to whether high-dose
chemotherapy (HDCT) improves survival compared to
standard-dose chemotherapy as first salvage therapy [3]. As
a matter of fact, HDCT demonstrated to be an effective
treatment, and is being steadily used worldwide as a salvage
therapy option for advanced GCT, mainly as second or
subsequent salvage therapy and always with the use of
tandem or triple course of carboplatin and etoposide [4–7].
Although, HDCT is thought to improve survival of GCT
patients with poorest prognosis, the long-term-side effects
of treatment may significantly impair the quality of life in
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patients who attain long-term remission. The risk of
developing secondary malignancies (SM) in the field of
GCT, after either chemotherapy or radiotherapy, was
assessed by several authors through population-based stu-
dies and prospective trials [8–20]. The main focus of these
studies was on patients diagnosed with stage I GCT who
received adjuvant treatment or on those with advanced GCT
who received first-line bleomycin, etoposide, and cisplatin
(BEP) chemotherapy. The negative impact of either treat-
ment options, causing a higher risk of developing solid SM
compared to the untreated population, is well documented:
the 20-year cumulative incidence of solid SM ~5%, whereas
the risk of developing hematologic SM is below 2%
[14, 18]. Conversely, very few information is available
regarding the effect of HDCT on the risk of developing SM
in GCT patients. The European Society for Blood and
Marrow Transplantation (EBMT) systematically collect
transplant data of patient from European and from a few
non-European countries, and then represents a well suited
platform for retrospective studies. We promoted a retro-
spective study aimed at evaluating the incidence and risk
factors for the development of SM in GCT patients who
received HDCT as part of their therapeutic strategy.
Patients and methods
Study design and patient population
The EBMT database was interrogated to identify suitable
patients for this study. Uniform data field, comprising
baseline characteristics and pathology information, and
HDCT regimen were collected using an Excel sheet, after
approval of the Institutional Review Board (IRB) and ethics
committee at each participating institution. Patient selection,
data extraction, quality control, and check for consistency
were made at the EBMT Office in Paris. Inclusion criteria
for the current analysis were: administration of the first
HDCT course until 2015, male gender, minimum age of 18
at first transplant, either gonadal or extragonadal primary
tumor origin. Receipt of any HDCT regimen was allowed,
followed by hematopoietic stem-cell rescue. Contralateral
and familial testicular cancers were excluded, as they were
all cases who developed concomitant GCT and non-GCT
malignancy, given the likelihood that these cases harbored
teratoma with malignant transformation. Leukemia and
myelodysplastic syndromes were jointly analyzed as
hematologic SM.
Statistical analyses
The primary study objective was to analyze the incidence
and the risk factors of SM development after HDCT in GCT
recipients. The secondary objective was to assess the out-
come after the diagnosis of SM, being OS the secondary
endpoint.
Patient, disease, and outcome characteristics were sum-
marized using descriptive statistics, with frequencies and
percentages used for categorical variables and medians and
range or interquartile range (IQR) for continuous variables.
Cumulative incidence methods were used to estimate the
time-to-SM diagnosis. To estimate the probability of
developing SM, the crude cumulative incidence was cal-
culated for all patients in a competing risk framework,
including death as the competing event. The date of first
HDCT course was taken as reference. Univariable,
competing-risk regression analysis was performed, as
described by Fine and Gray [21], and described as pro-
portional hazard regression rates, to identify the effect of
prognostic factors on the cumulative incidence function for
competing risks data. Multivariable analyses were not
undertaken due to the limited number of events. The
potential risk factors evaluated by univariable analysis
were: age at the time of HDCT delivery, GCT histology,
source of stem cells, the number of HDCT cycles, and the
conditioning regimen. The Gray test was used to compare
the cumulative incidence curves of any risk factor among
different groups in the presence of a competing risk (always
defined as death from any other cause than hematologic or
solid tumors) [22].
Complete case analysis was performed, and no imputa-
tion was performed for missing data. Kaplan–Meier curves
were used to estimate OS since the diagnosis of SM, and the
comparison of OS according to the type of SM was made
via the log-rank test. All tests were two-sided and statistical
significance was defined as a p-value of 0.05 or less. The
analyses were conducted using SAS (SAS Institute Inc.,
Cary, NC, USA) and R software (http://www.r-project.org/,
accessed 30 June 2017).
Results
Patient identification and characteristics
The flow of the case-selection is shown in Supplementary
Figure 1. A total of 5295 patients were found in the registry,
5218 of whom suitable for analyses, treated with HDCT in
the years 1981–2015. As expected, there was a ratio of 4:1
between non-seminomatous and pure seminomatous cases.
Finally, 59 patients, who developed SM in the period
1984–2014, registered from 33 countries, constituted the
study population. Patient characteristics are described in
Table 1, for both the screened and selected patients. Median
age at the time of HDCT delivery was 32 years (interquartile
range [IQR]: 25–38) in the study group, whereas the median
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age at the time of SM diagnosis was 41 years (IQR 36–49).
SM was represented by 23 hematologic SM and 34 solid SM
(2 cases had SM unclassified). The median time-to-solid SM
development was 61.8 months (IQR: 13.8–129.5) and the
median time-to-hematologic SM occurrence 38.8 months
(IQR: 14.5–81.1). The median follow-up duration was 3.8
years (IQR: 0.93–9.18), and the median OS from HDCT was
8.5 years (IQR: 0.8–not reached).
Several solid tumors were recorded and are shown in
Supplementary Table 1. Information on prior to radio-
therapy delivery was largely missing in the screened
population, as shown in Supplementary Table 2, but it was
made available in all cases with SM. Only two of them
(3.4%) had received radiotherapy, after first-line che-
motherapy, and none of them received post HDCT radio-
therapy. In regards to the available conditioning regimen
information, about half of the screened patients received the
current standard, i.e., high-dose carboplatin and etoposide.
Cumulative incidence of SM and competing-risk
regression analyses
The crude cumulative incidence of SM by type of malig-
nancy is shown in Table 2 and Fig. 1, whereas the cumu-
lative incidence of death from any cause and of SM (any
type) is provided in Supplementary Figure 2. The incidence
was similar until the 10-year cutoff, and diverged at 20
years, being 4.17% (95% CI: 1.78–6.57) for solid SM, and
1.37 (95% CI: 0.47–2.27) for hematologic SM.
We then stratified patients according to the arbitrary
cutoff of 40 years of age at the time of first HDCT course
(Supplementary Table 3). The difference remained
numerically significant, and the CCI of solid SM at 20 years
for patients aged ≥40 years was 6.85% (95% CI: 0–15.47,
Supplementary Figure 3A). The results of the univariable
competing-risk analyses are shown in Table 3. Older age
was the only statistically significant factor associated with
SM development (HR for the class “≥40 years” versus “<40
years”: 2.28, 95% CI: 1.35–3.84, p= 0.004). The associa-
tion was significant for hematologic SM (HR: 3.48, 95% CI:
1.54–7.86, p= 0.004), whereas it was lost for solid SM
(HR: 1.59, 95% CI: 0.76–3.32, p= 0.234; the correspond-
ing estimates of CCI are provided in Supplementary Fig-
ures 3B, 3C).
Overall survival after SM occurrence
Kaplan–Meier OS curves since the diagnosis of SM are
shown in Fig. 2. Patients developing solid SM had longer
survival compared to those with hematologic SM. Median
OS with solid SM was 34.4 months (IQR: 11.8–not
estimable) versus 8.6 months (IQR: 2.6–20.0) after hema-
tologic SM diagnosis (p= 0.003).
Discussion
To the authors’ knowledge, we have reported an analysis of
incidence of SM from the largest population of GCT
patients who have received HDCT to date. The adminis-
tration of high-dose carboplatin and etoposide for chemor-
efractory GCT has become increasingly popular during the
last 10 years, owing to the results from large retrospective
analyses [5], and it represents the only consolidated indi-
cation of HDCT as standard practice in adult solid tumors.
In general, HDCT is a highly effective option for relapsed,
high-risk patients with GCT, and the proportion of patients
who can benefit with long-term remission (i.e., cure of the
disease) varies according to the presence of prognostic
factors, and may be >50% in good-risk patients [6]. Con-
sequently, long-term toxicities of chemotherapy are well-
recognized among GCT experts. These side effects may
have important implications for follow-up planning and
duration, and the available recommendations for the follow-
up after salvage therapy or HDCT in these patients remain
elusive. SM in particular is a potentially life-threatening late
effect of GCT therapy. Regarding the risk of developing
SM after treatment for GCT, most of the population-level
studies evaluated the effect of adjuvant treatment in clinical
stage I patients, and only a few of them reported the effects
of chemotherapy for advanced disease. In these studies, the
increased risk of developing solid tumors was largely
attributed to radiotherapy, especially in older patients,
accounting for a sizeable increment of SM development
compared to the age-matched general population [23–25].
In regard to chemotherapy effect, some population-based
data and retrospective analyses are available to provide
guidance for patient counseling [16–20]. These long-dated
studies assessed the risk of developing secondary leukemia
after HDCT, and identified the total cumulative dose of
etoposide >2 gr/m2 as potentially associated with an
acceptable risk of about 2% of developing acute myeloid
leukemia. Regarding the risk of developing solid SM, it
remains unclear whether HDCT administration portends an
increased risk compared to standard chemotherapy. Overall,
the present CCI results are consistent with the available
data, and the cumulative incidence curves of solid SM are
close to those reported with standard-dose chemotherapy.
As a strength of our analyses, we were able to show that
the trends of SM occurrence after HDCT were different
between solid and hematologic tumors. The former showed
a delayed increment to above 4% after 20 years, and this
observation is originally reported here for HDCT, whereas
the latter showed a less significant raise to about 1.4%,
which is in line with the published data [16–20]. Despite
this, we were unable to run multivariate models due to the
small number of SM events, but our observations are
unlikely biased by the effect of age, which was not
724 A. Necchi et al.
associated with the risk of developing solid neoplasms.
Conversely, as an additional interesting finding, older age
was significantly associated with the risk of developing
hematologic cancers or myelodysplasia. This finding is
likely the result of a secondary effect of HDCT. Further-
more, we were able to report the prognostic impact of solid
versus hematologic SM development in these patients.
These outcomes pose additional warning on the adminis-
tration of HDCT in patients older than 40 years, and warrant
additional studies.
There are of course some critical limitations to
acknowledge in our study. First, the EBMT database lack of
potentially important baseline data. For example, the risk of
hematologic cancers occurring in primary mediastinal non-
seminoma is well acknowledged in the literature [26], and
the information of the site of the primary tumor could have
allowed us to more finely delineate the characteristics of
patients at higher risk of developing hematologic SM.
Additional data were unaccounted for in this study: the
subtype of acute leukemia, including the information on the
underlying cytogenetic alterations, and most importantly the
total burden of chemotherapy administration (i.e., number
of chemotherapy regimens the patients received for GCT,
added to HDCT), that might have had an impact on the risk
Table 1 Baseline characteristics of the total analyzed patients from the









1981–1989 175 (3.4) 2 (3.4)
1990–1999 1447 (27.8) 23 (39.0)
2000–2009 2136 (40.9) 29 (49.1)
2010–2015 1460 (27.9) 5 (8.5)
Characteristic No. (%)
Age at the time of HDCT—years
Median (interquartile range) 32 (26–39) 32 (25–38)
Histology of GCT
Non-seminoma 1972 (37.8) 29 (49.2)
Seminoma 486 (9.3) 8 (13.6)
GCT unclassified 2760 (52.9) 22 (37.2)
Source of hematopoietic stem cells
Peripheral blood 4573 (88.4) 51 (86.4)
Bone marrow 599 (11.6) 8 (13.6)
Missing 46 —
Number of HDCT courses
1 2639 (50.6) 31 (52.5)
2 1237 (23.7) 19 (32.2)
>2 1337 (25.7) 9 (15.3)
Missing 5 —
HDCT conditioning regimen
CBDCA-VP16 1310 (25.1) 8 (13.6)
Other 1805 (34.6) 23 (39.0)a
Missing 2103 (40.3) 28 (47.4)
Country of origin
Germany 1831 (35.1) 21 (35.6)
France 957 (18.3) 12 (20.2)
United Kingdom 481 (9.2) 5 (8.5)
Italy 454 (8.7) 3 (5.1)
Switzerland 197 (3.8) 4 (6.8)
Austria 176 (3.4) 2 (3.4)
Spain 131 (2.5) —
Sweden 131 (2.5) 2 (3.4)
Turkey 128 (2.4) —
Poland 115 (2.2) 1 (1.7)
The Netherlands 115 (2.2) 5 (8.5)
Belgium 85 (1.6) —
Czech Republic 77 (1.5) 1 (1.7)
Israel 44 (0.8) —
Finland 43 (0.8) 1 (1.7)
Denmark 39 (0.7) —





(N= 5218) (N= 59)
Greece 33 (0.6) —
Lithuania 27 (0.5) 1 (1.7)
Portugal 22 (0.4) —
Australia 16 (0.3) —
Croatia 16 (0.3) —
Bulgaria 13 (0.2) —
Jordan 9 (0.2) —
New Zealand 9 (0.2) —
Russia 8 (0.2) —
Lebanon 6 (0.1) —
Argentina 4 (0.08) —
Iran 4 (0.08) —
Serbia 3 (0.06) —
Romania 2 (0.04) —
Slovenia 2 (0.04) —
South Africa 2 (0.04) —
CBDCA carboplatin, GCT germ cell tumor, HDCT high-dose
chemotherapy, SM secondary malignancy, VP16 etoposide
aConsisting of the following regimens: carboplatin, etoposide, ifosfa-
mide (n= 14), carboplatin, etoposide, paclitaxel (n= 2), carboplatin,
etoposide, melphalan (n= 1), carboplatin, etoposide, cyclophosphamide
(CarboPec, n= 3), cyclophosphamide, and etoposide (n= 3)
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of developing SM. The total dose of the drugs used as
induction regimens was not recorded as well. However, the
total doses of carboplatin and etoposide administered in the
standard regimens, as well as in the other mixed regimens
published in the literature, is largely comparable [3]. The
effect of additional drugs administration on the risk of SM
development remains elusive.
Second, despite our study covered a 34-year period of
HDCT administration, the quality of the follow-up for alive
patients was suboptimal, resulting in a median follow-up
duration of <5 years which may have substantially limited
our possibility to observe additional cases. Consequently,
the number of patients at risk at long-term follow-up was
small, thus affecting the reliability of the cumulative inci-
dence estimates. Third, we were unable to analyze the age
factor, which resulted significantly associated with hema-
tologic SM occurrence, as a continuous variable due to the
small numbers. For this reason, and based on the observed
distribution of age (the third quartile being set at 38 years in
the study group), we arbitrarily set the cutoff at 40 year to
tackle the effect of older age at first transplant, like we did
in a previous study from the EBMT database [27]. This
cutoff may be further refined with additional studies. Of
note, the analyses comprised a huge number of patients
from diverse countries: for these reasons, and due to the fact
that the overall incidence of SM was rather low in our
study, we did not rely on the incidence data of SM from the
National or European registries in order to provide the
standardized incidence ratios, and any attempt to perform
age-matched cohort analyses is very hard and not suffi-
ciently reliable in our view. Finally, other unexplained
environmental risk factors (e.g., smoking) could have con-
tributed to the risk of developing SM, especially solid SM.
In conclusion, in our large, multinational series of GCT
patients treated with HDCT, there was not an exceedingly
high occurrence of hematologic SM during the follow-up
period, but an association with age older than 40 at the time
of HDCT delivery was found. While the small sample size
of patients at risk does not allow firm conclusions, it would
appear that there is an increased risk of solid tumors at after
15 years of follow-up, similar to standard-dose che-
motherapy. Our observation dictates the need for long-term
surveillance in these patients (i.e., at least 20 years),
although special follow-up protocols do not seem necessary
after HDCT. Conversely, caution is needed for the
Table 2 Crude cumulative
incidence of SM
Type of SM 5 y CCI, % (95% CI) 10 y CCI, % (95% CI) 20 y CCI, % (95% CI)
Solid SM 0.52 (0.27–0.77) 0.86 (0.49–1.24) 4.17 (1.78–6.57)
Hematologic SM 0.51 (0.26–0.76) 0.68 (0.36–0.99) 1.37 (0.47–2.27)















































93 69 51 31
1 2 3 4 5 6 7 8 9 10
Years
No. patients at risk
Overall
11 12 13 14 15 16 17 18 19 20
Fig. 1 Cumulative incidence of secondary malignancy with death as a
competing risk. Red curve: incidence of hematologic secondary
malignancy; dotted blue curve: incidence of solid secondary malig-
nancy. (Color figure online)
Table 3 Univariable competing-risk regression model to analyze the
association of clinical factors with SM occurrence
Factor HR 95% CI p-value*
Age (years) 0.004
● ≥40 versus <40 2.28 1.35–3.84
GCT histology 0.613
● Non-seminoma Reference Reference
● Seminoma 1.25 0.57–2.72
● Unclassified 0.84 0.49–1.44
Source of stem cells 0.286
● Bone marrow versus
peripheral blood
0.67 0.33–1.38
Number of HDCT courses 0.223
● 1 Reference Reference
● 2 1.53 0.86–2.70




● CBDCA-VP16 Reference Reference
● Other 1.22 0.55–2.70
● Unclassified 1.14 0.53–2.48
CBDCA carboplatin, CI confidence interval, GCT germ cell tumor,
HDCT high-dose chemotherapy, HR hazard ratio, SM secondary
malignancy, VP16 etoposide
*Fine and Gray test p-value
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administration of HDCT in patients older than 40 years,
pending validation of our findings with additional studies
with longer median follow-up.
Notes
Data were presented in part in a poster session, at the 2017
Genitourinary Cancers Symposium, February 16-18th,
2017, Orlando (FL), USA.
Data were presented in part in a poster session, at the
2017 Annual meeting of the European Association of
Urology (EAU), March 24-28th, 2017, London, United
Kingdom.
Data were presented in part in a poster session, at the
2017 Annual Meeting of the American Society of Clinical
Oncology (ASCO), June 2-6th, 2017, Chicago (IL), USA.
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